What are the differences between tardive dyskinesia (TD) and extrapyramidal symptoms (EPS), and which antipsychotic agents have the lowest risk of these side effects?

Atypical Antipsychotics Have the Lowest Risk of Both EPS and TD

Atypical (second-generation) antipsychotics are superior to typical (first-generation) antipsychotics for minimizing both extrapyramidal symptoms (EPS) and tardive dyskinesia (TD), with olanzapine, quetiapine, and aripiprazole showing the lowest risk profiles. 1, 2

Key Differences Between TD and EPS

Extrapyramidal Symptoms (EPS)

EPS are acute movement disorders that typically appear within hours to weeks of starting antipsychotic therapy or after dose increases 2, 3. They include three main subtypes:

• Dystonia: Sudden spastic muscle contractions affecting neck, eyes (oculogyric crisis), or torso. Life-threatening laryngeal dystonia can present as choking or stridor. Occurs after first few doses, more common in young males 2, 4

• Drug-induced Parkinsonism: Bradykinesia, tremors, and rigidity mimicking Parkinson's disease. Can be difficult to distinguish from negative symptoms of schizophrenia 2, 4

• Akathisia: Subjective severe restlessness with pacing and physical agitation. Often misinterpreted as psychotic agitation and leads to medication noncompliance 4

Tardive Dyskinesia (TD)

TD is a late-onset, potentially irreversible movement disorder characterized by rapid involuntary facial movements (blinking, grimacing, chewing, tongue protrusion) and extremity/truncal movements 2. Critical distinguishing features:

• Appears after at least 3 months of antipsychotic treatment, typically much longer 3
• May persist permanently even after medication discontinuation 4
• Occurs in 5% of young patients per year on typical antipsychotics 2
• Can reach 50% incidence in elderly patients after 2 years of continuous typical antipsychotic use 1

Important caveat: Respiratory dyskinesia is often undiagnosed and can lead to recurrent aspiration pneumonia 2

Antipsychotics Ranked by Movement Disorder Risk

Lowest Risk (Preferred First-Line)

Based on the most recent guideline data 2:

1. Aripiprazole: 0 ms QT prolongation, minimal EPS risk
2. Olanzapine: Annual TD incidence 2.8%, EPS incidence 7.7% 5
3. Quetiapine: 6 ms QT prolongation, low EPS burden

Moderate Risk

1. Risperidone: EPS may occur at ≥2 mg/day 1; significantly higher TD risk than olanzapine 5
2. Clozapine: Lowest EPS/TD risk but reserved for treatment-resistant cases due to agranulocytosis and seizure risks 4

Highest Risk (Avoid When Possible)

1. Typical antipsychotics (haloperidol, fluphenazine, thioridazine):
   • Annual TD incidence 5.4% in adults 6
   • EPS incidence up to 32.8% with depot formulations 5
   • Should be avoided due to "significant, often severe side effects" and inherent risk of irreversible TD 1

Clinical Algorithm for Antipsychotic Selection

Step 1: Start with atypical antipsychotics as first-line 7

• Prioritize olanzapine, quetiapine, or aripiprazole based on metabolic profile tolerance
• Avoid typical antipsychotics unless atypicals fail or are not tolerated 1

Step 2: Monitor for movement disorders

• Baseline Abnormal Involuntary Movement Scale (AIMS) before starting 4
• Reassess every 3-6 months for TD 4
• Watch for acute EPS in first weeks of treatment

Step 3: If EPS develops

• Dystonia: Treat immediately with anticholinergic (benztropine) or antihistamine 4, 8
• Parkinsonism: Lower dose, switch to another atypical, or add amantadine (preferred over anticholinergics if TD risk exists) 3
• Akathisia: Lower dose, switch medication, add beta-blocker or benzodiazepine 8

Step 4: If TD develops

• Do not use anticholinergics - they worsen TD 3, 9
• Switch to atypical antipsychotic if on typical agent 4
• Consider VMAT2 inhibitors (valbenazine, deutetrabenazine) for moderate-to-severe TD 8
• Continue current medication only if patient is in full remission and any change risks relapse 4

Critical Pitfalls to Avoid

Never use anticholinergics long-term: They impair cognition, worsen TD, and have questionable benefit beyond acute EPS management 9. Gradual withdrawal improves cognition and TD without significant EPS relapse in stable patients 9.

Don't confuse akathisia with psychotic agitation: This leads to inappropriate dose increases, worsening the problem 4.

High-potency typicals (haloperidol) cause more EPS; low-potency typicals (thioridazine, chlorpromazine) cause more anticholinergic effects and sedation 4. Neither is preferable - use atypicals instead.

Children and adolescents have higher EPS risk than adults and may experience up to 50% incidence of tardive or withdrawal dyskinesia 4.

The evidence consistently demonstrates that atypical antipsychotics reduce both mortality (through lower TD rates) and improve quality of life (through reduced movement disorder burden) compared to typical agents 7, 6.